CC
CTNM

Commodore Capital’s Contineum Therapeutics CTNM Stock Holding History

Commodore Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-816,326
Closed -$9.33M – 44
2025
Q4 		$9.33M Buy
+816,326
New +$9.31M 0.62% 29

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Commodore Capital's CTNM Position: Q1 2026 in Review

Commodore Capital sold out of Contineum Therapeutics (CTNM) in Q1 2026, closing a stake of 816,326 shares — an estimated $9.33M sold.

Commodore Capital first reported a position in CTNM in Q4 2025 and held it in 1 quarter. The position peaked at $9.33M in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Commodore Capital reported no remaining Contineum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Commodore Capital sold 816,326 Contineum Therapeutics shares in Q1 2026, an estimated $9.33M.
  • Commodore Capital first reported a position in Contineum Therapeutics in Q4 2025 and held it in 1 quarter.
  • Commodore Capital's Contineum Therapeutics position peaked at $9.33M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.